lobbying_activities: 1406473
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1406473 | fc313776-8f9a-496a-86b4-82e5734be4c9 | Q2 | APOTEX CORP. | 310973 | APOTEX CORP. | 2013 | second_quarter | PHA | S. 504, The Fair and Immediate Release of Generics Act, provisions relating to market blockages caused by parked 180 day exclusivity periods S. 214, The Preserve Access to Affordable Pharmaceuticals Act, provisions relating to the legality of "reverse payment" patent settlementsFederal Trade Commission v. Actavis Supreme Court Case No. 12-416 as this case pertains to S. 504, S. 214, and to federal policy on "reverse payment" settlements Potential legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing H.R. 1919, the Safeguarding America's Pharmaceutical Act of 2013, S. 959, the Pharmaceutical Compounding Quality and Accountability Act, Title II, Drug Supply Chain Security, provisions relating to the establishment of a federal track and trace system for pharmaceuticals Federal policy relating to the adoption of an electronic labeling system for pharmaceuticals, inlcuding as proposed in HR 1919 S. 1244, Fiscal Year 2014 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations bill, Title VI, Related Agency and Food and Drug Administration, provisions relating to the sequester's impact on the generic drug user fee program | Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE | 140000 | 0 | 0 | 2013-07-15T10:22:09.377000-04:00 |